Related Experiment Video
Updated: Aug 31, 2025
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
3.0K
Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients
Tabatha Petrillo1, Elisa Semprini1, Veronica Tomatis1
1Gynecological Endocrinology Center, Department of Obstetrics and Gynecology, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Biomedicines
|August 26, 2022
Summary
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women. This review explores complementary treatments that target insulin resistance, a key feature of PCOS.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Reproductive Health
Background:
- Polycystic ovary syndrome (PCOS) is the most common endocrine-metabolic disorder in women of reproductive age.
- Diagnosis relies on the Rotterdam criteria, with insulin resistance and hyperinsulinemia being key etiological factors.
- PCOS presents with diverse clinical manifestations, complicating treatment strategies.
Purpose of the Study:
- To review and analyze complementary and integrative treatments for PCOS.
- To focus on substances that counteract insulin resistance in PCOS patients.
- To provide clinical insights into these alternative therapeutic approaches.
Main Methods:
- Literature review of complementary substances used in PCOS management.
- Analysis of studies focusing on insulin resistance and hyperinsulinemia in PCOS.
- Synthesis of clinical insights from various integrative treatments.
Main Results:
- A variety of integrative treatments have been reported to effectively manage insulin resistance in PCOS.
- Tailored therapeutic strategies are essential, considering BMI, diabetes predisposition, and pregnancy desires.
- Complementary substances offer potential avenues for PCOS management.
Conclusions:
- Insulin resistance is a central aspect of PCOS pathophysiology.
- Integrative treatments show promise in managing PCOS, particularly insulin resistance.
- Personalized treatment plans are crucial for optimizing outcomes in PCOS patients.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
272
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
272
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
241
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
241
01:24Glucagon-like Receptor Agonists
397
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
397
01:23Dipeptidyl Peptidase 4 Inhibitors
236
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
236
01:06Oral Hypoglycemic Agents: Glinides
235
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
235
01:16Insulin: Dosing Regimen and Adverse Effects
235
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
235